Loading...
Market
Region receiving largest share of Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Distribution reports from Global Fund and PEPFAR, regional health organization updates
Story
Global Fund and PEPFAR to Distribute Lenacapavir, 100% Success Rate, to 2 Million People by 2026
Dec 17, 2024, 03:09 PM
A new long-acting preventive drug for HIV, known as Lenacapavir, is set to be distributed in the world's poorest countries by late 2025 or early 2026. This initiative is part of a coordinated effort by the Global Fund and PEPFAR, aiming to reach 2 million people with the drug, which has shown 100% success in trials. Health officials believe that this drug could significantly reduce global HIV infections and accelerate the fight against the virus by 2030.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
USA • 25%
European Union • 25%
Africa • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Other • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
1-4 countries • 25%
5-9 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
0-10 • 25%
11-30 • 25%
31-60 • 25%
61-120 • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
Less than 10% • 25%
10%-30% • 25%
31%-50% • 25%
More than 50% • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%